Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Benazepril hydrochloride
Drug ID BADD_D00228
Description Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure[A838,A837]. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor[A836].
Indications and Usage Benazepril is indicated for the treatment of hypertension[A840]. It may be used alone or in combination with thiazide diuretics[FDA Label].
Marketing Status approved; investigational
ATC Code C09AA07
DrugBank ID DB00542
KEGG ID D00620
MeSH ID C044946
PubChem ID 5362123
TTD Drug ID D0U3EC
NDC Product Code 51927-0104; 65862-116; 23155-749; 42291-162; 43063-679; 50090-3243; 51655-388; 53746-751; 63629-8035; 70771-1149; 65129-2021; 23155-750; 51407-463; 51655-065; 53746-752; 53746-754; 60760-352; 63187-500; 68788-7845; 70771-1150; 13612-0002; 65862-117; 71052-173; 23155-752; 51655-202; 65162-753; 68071-1026; 71205-320; 55154-4344; 63187-499; 70934-608; 71335-0011; 72162-1816; 30698-449; 43063-677; 50090-5751; 55154-4343; 65162-754; 68788-9313; 68788-9327; 70518-2125; 71335-1086; 50090-3775; 50268-109; 51407-465; 51655-617; 61919-756; 65162-751; 68071-2929; 70518-3171; 70518-3528; 71335-0457; 71335-0854; 42291-163; 43547-338; 50090-3359; 50268-110; 51407-462; 51407-464; 60760-351; 63187-393; 63187-906; 68788-6889; 70771-1148; 71335-1365; 44139-0026; 43547-336; 50090-5750; 53002-1233; 65862-118; 68788-6957; 70518-1640; 70518-3172; 70771-1151; 70934-483; 71335-0267; 71335-1299; 23155-751; 42291-161; 51655-755; 53746-753; 70934-983; 72189-110; 15308-0900; 17404-0016; 51927-0105; 58159-086; 65862-346; 30698-448; 43547-337; 50268-112; 53002-1248; 55700-291; 65162-752; 68071-1770; 70518-3074; 71205-244; 71335-0078; 22568-1136; 51927-0036; 64220-145; 30698-450; 43063-748; 43547-335; 50268-111; 51655-066
UNII N1SN99T69T
Synonyms benazepril | benazapril | benzazepril | Labopal | Lotensin | Cibacène | Cibacen | Briem | benazepril hydrochloride | CGS-14824-A | CGS-14824A
Chemical Information
Molecular Formula C24H29ClN2O5
CAS Registry Number 86541-74-4
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC2CCC3=CC=CC=C3N(C2=O)CC(=O)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.004--Not Available
Melaena24.07.02.013; 07.12.02.004--Not Available
Muscle spasms15.05.03.004--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Neuritis17.09.03.001--Not Available
Neutropenia01.02.03.004--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral02.05.04.007; 14.05.06.011; 08.01.07.007--
Oesophagitis07.08.05.001--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Palpitations02.11.04.012--
Pancreatitis07.18.01.001--
Paraesthesia17.02.06.005; 23.03.03.094--
Pemphigus23.03.01.005; 10.04.02.003--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Photosensitivity reaction23.03.09.003--
Pollakiuria20.02.02.007--
Polyuria20.02.03.002--Not Available
Proteinuria20.02.01.011--
Pruritus23.03.12.001--
Pulmonary eosinophilia22.01.01.009; 01.02.04.006--Not Available
Rash23.03.13.001--Not Available
Respiratory disorder22.02.07.002--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Shock24.06.02.002--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages